These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

898 related articles for article (PubMed ID: 31382100)

  • 21. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Psychedelics in Treating Anxiety Disorders.
    Feulner L; Sermchaiwong T; Rodland N; Galarneau D
    Ochsner J; 2023; 23(4):315-328. PubMed ID: 38143548
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review.
    Romeo B; Hermand M; Pétillion A; Karila L; Benyamina A
    J Psychiatr Res; 2021 May; 137():273-282. PubMed ID: 33730602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.
    Reiche S; Hermle L; Gutwinski S; Jungaberle H; Gasser P; Majić T
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():1-10. PubMed ID: 28947181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of Psychedelics in Treatment-Resistant Depression.
    Kamal S; Jha MK; Radhakrishnan R
    Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer.
    Dos Santos RG; Bouso JC; Hallak JEC
    BMC Psychiatry; 2019 Oct; 19(1):321. PubMed ID: 31660905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Psychedelics for existential distress in terminally ill patients].
    Schimmel N; Breeksema JJ; Veraart JKE; van den Brink W; Schoevers RA
    Tijdschr Psychiatr; 2020; 62(8):659-668. PubMed ID: 32816294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.
    Mertens LJ; Preller KH
    Pharmacopsychiatry; 2021 Jul; 54(4):176-190. PubMed ID: 33472250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies.
    Calleja-Conde J; Morales-García JA; Echeverry-Alzate V; Bühler KM; Giné E; López-Moreno JA
    Addict Biol; 2022 Nov; 27(6):e13229. PubMed ID: 36301215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.
    Ko K; Kopra EI; Cleare AJ; Rucker JJ
    J Affect Disord; 2023 Feb; 322():194-204. PubMed ID: 36209780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Default Mode Network Modulation by Psychedelics: A Systematic Review.
    Gattuso JJ; Perkins D; Ruffell S; Lawrence AJ; Hoyer D; Jacobson LH; Timmermann C; Castle D; Rossell SL; Downey LA; Pagni BA; Galvão-Coelho NL; Nutt D; Sarris J
    Int J Neuropsychopharmacol; 2023 Mar; 26(3):155-188. PubMed ID: 36272145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics.
    Hovmand OR; Poulsen ED; Arnfred S
    J Psychopharmacol; 2024 Jan; 38(1):19-32. PubMed ID: 37969069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychedelics as Medicines: An Emerging New Paradigm.
    Nichols DE; Johnson MW; Nichols CD
    Clin Pharmacol Ther; 2017 Feb; 101(2):209-219. PubMed ID: 28019026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dosing Psychedelics and MDMA.
    Liechti ME; Holze F
    Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
    Dos Santos RG; Hallak JE; Baker G; Dursun S
    J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology.
    Kelly DF; Heinzerling K; Sharma A; Gowrinathan S; Sergi K; Mallari RJ
    Neurosurgery; 2023 Apr; 92(4):680-694. PubMed ID: 36512813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychedelic perceptions: mental health service user attitudes to psilocybin therapy.
    Corrigan K; Haran M; McCandliss C; McManus R; Cleary S; Trant R; Kelly Y; Ledden K; Rush G; O'Keane V; Kelly JR
    Ir J Med Sci; 2022 Jun; 191(3):1385-1397. PubMed ID: 34131812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.